The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Challenges of Convalescent Plasma Infusion Therapy in Middle East Respiratory Coronavirus Infection: A Single Centre Experience
Open accessAbstract
Background: The effects of convalescent plasma (CP) infusion, one of the treatment options for severe Middle East respiratory syndrome coronavirus (MERS-CoV) infections, have not yet been evaluated. Methods: Serological responses of CP-infused MERS patients during the 2015 Korean MERS outbreak at a tertiary care centre were evaluated. Serological activity was evaluated with anti-MERS-CoV enzyme-linked immunosorbent assay (ELISA) immunoglobulin (Ig)G, ELISA IgA, immunofluorescence assay IgM and plaque reduction neutralization test (PRNT). Donor plasma and one or two recipient's serum samples per week of illness including one taken the day after each CP infusion were evaluated. For sensitivity and specificity analysis of ELISA IgG in predicting neutralization activity, a data set of 138 previously evaluated MERS-CoV-infected patients was used. Results: Three of thirteen MERS patients with respiratory failure received four CP infusions from convalesced MERS-CoV-infected patients, and only two of them showed neutralizing activity. Donor plasma with a PRNT titre 1:80 demonstrated meaningful serological response after CP infusion, while that with a PRNT titre 1:40 did not. ELISA IgG predicted neutralization activity of a PRNT titre ≥1:80 with more than 95% specificity at a cutoff optical density (OD) ratio of 1.6, and with 100% specificity at an OD ratio of 1.9. Conclusions: For effective CP infusion in MERS, donor plasma with a neutralization activity of a PRNT titre ≥1:80 should be used. ELISA IgG could substitute for the neutralization test in resource-limited situations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J. K., Cleary, P., Khaw, F.-M., Lim, W. S., Makki, S., Rooney, K. D., Convalescent Plasma Study Group, Nguyen-Van-Tam, J. S., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu396 · Cited by 983
Min, C.-K., Cheon, S., Ha, N.-Y., Sohn, K. M., Kim, Y., Aigerim, A., Shin, H. M., Choi, J.-Y., Inn, K.-S., Kim, J.-H., et al. (2016) · Scientific Reports · doi:10.1038/srep25359 · Cited by 364
Self-citationAssays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections
Corman, V. M., Müller, M. A., Costabel, U., Timm, J., Binger, T., Meyer, B., Kreher, P., Lattwein, E., Eschbach-Bludau, M., Nitsche, A., et al. (2012) · Eurosurveillance · doi:10.2807/ese.17.49.20334-en · Cited by 360
Self-citationMERS Coronavirus Neutralizing Antibodies in Camels, Eastern Africa, 1983–1997
Müller, M. A., Corman, V. M., Jores, J., Meyer, B., Younan, M., Liljander, A., Bosch, B.-J., Lattwein, E., Hilali, M., Musa, B. E., et al. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2012.141026 · Cited by 306
Self-citationFeasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia
Arabi, Y. M., Hajeer, A. H., Luke, T., Raviprakash, K., Balkhy, H., Johani, S., Al-Dawood, A., Al-Qahtani, S., Al-Omari, A., Al-Hameed, F., et al. (2016) · Emerging Infectious Diseases · doi:10.3201/eid2209.151164 · Cited by 244
Arabi, Y., Balkhy, H., Hajeer, A. H., Bouchama, A., Hayden, F. G., Al-Omari, A., Al-Hameed, F. M., Taha, Y., Shindo, N., Whitehead, J., et al. (2015) · SpringerPlus · doi:10.1186/s40064-015-1490-9 · Cited by 202
Enria, D., Fernandez, N., Briggiler, A., Levis, S., & Maiztegui, J. (1984) · The Lancet · doi:10.1016/s0140-6736(84)90299-x · Cited by 184
Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea
Park, W. B., Perera, R. A. P. M., Choe, P. G., Lau, E. H. Y., Choi, S. J., Chun, J. Y., Oh, H. S., Song, K., Bang, J. H., Kim, E. S., et al. (2015) · Emerging infectious diseases · doi:10.3201/eid2112.151421 · Cited by 150
Mustafa, S. M., Balkhy, H. H., & Gabere, M. N. (2017) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2017.08.009 · Cited by 150
Ko, J., Park, G. E., Lee, J. Y., Lee, J., Cho, S. Y., Ha, Y. E., Kang, C., Kang, J., Kim, Y., Huh, H. J., et al. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.08.005 · Cited by 138
Self-citation
Cited by
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004168117 · Cited by 1,960
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140
The convalescent sera option for containing COVID-19
Casadevall, A., & Pirofski, L.-A. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138003 · Cited by 903
Deployment of convalescent plasma for the prevention and treatment of COVID-19
Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B., Winters, J. L., van Buskirk, C., Grossman, B. J., Joyner, M., Henderson, J. P., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138745 · Cited by 799
Neutralizing monoclonal antibodies for treatment of COVID-19
Taylor, P. C., Adams, A. C., Hufford, M. M., de la Torre, I., Winthrop, K., & Gottlieb, R. L. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00542-x · Cited by 732
Sharma, A., Tiwari, S., Deb, M. K., & Marty, J. L. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106054 · Cited by 705
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Lee, W. S., Wheatley, A. K., Kent, S. J., & DeKosky, B. J. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00789-5 · Cited by 676
Ashour, H. M., Elkhatib, W. F., Rahman, M. M., & Elshabrawy, H. A. (2020) · Pathogens · doi:10.3390/pathogens9030186 · Cited by 607
An Update on Current Therapeutic Drugs Treating COVID-19
Wu, R., Wang, L., Kuo, H.-C. D., Shannar, A., Peter, R., Chou, P. J., Li, S., Hudlikar, R., Liu, X., Liu, Z., et al. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00216-7 · Cited by 599
Convalescent plasma in Covid-19: Possible mechanisms of action
Rojas, M., Rodríguez, Y., Monsalve, D. M., Acosta-Ampudia, Y., Camacho, B., Gallo, J. E., Rojas-Villarraga, A., Ramírez-Santana, C., Díaz-Coronado, J. C., Manrique, R., et al. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102554 · Cited by 491
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Arvin, A. M., Fink, K., Schmid, M. A., Cathcart, A., Spreafico, R., Havenar-Daughton, C., Lanzavecchia, A., Corti, D., & Virgin, H. W. (2020) · Nature · doi:10.1038/s41586-020-2538-8 · Cited by 485
Middle East respiratory syndrome
Memish, Z. A., Perlman, S., Van Kerkhove, M. D., & Zumla, A. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33221-0 · Cited by 479
Immune response in COVID-19: A review
Chowdhury, M. A., Hossain, N., Kashem, M. A., Shahid, M. A., & Alam, A. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.07.001 · Cited by 445
Ahn, J. Y., Sohn, Y., Lee, S. H., Cho, Y., Hyun, J. H., Baek, Y. J., Jeong, S. J., Kim, J. H., Ku, N. S., Yeom, J.-S., et al. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e149 · Cited by 352
Self-citationSARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Uddin, M., Mustafa, F., Rizvi, T. A., Loney, T., Al Suwaidi, H., Al-Marzouqi, A. H. H., Kamal Eldin, A., Alsabeeha, N., Adrian, T. E., Stefanini, C., et al. (2020) · Viruses · doi:10.3390/v12050526 · Cited by 319
Wang, K., Long, Q.-X., Deng, H.-J., Hu, J., Gao, Q.-Z., Zhang, G.-J., He, C.-L., Huang, L.-Y., Hu, J.-L., Chen, J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1143 · Cited by 218
Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals
Beaudoin-Bussières, G., Laumaea, A., Anand, S. P., Prévost, J., Gasser, R., Goyette, G., Medjahed, H., Perreault, J., Tremblay, T., Lewin, A., et al. (2020) · mBio · doi:10.1128/mbio.02590-20 · Cited by 189
Safety of Plasma Infusions in Parkinson's Disease
Parker, J. E., Martinez, A., Deutsch, G. K., Prabhakar, V., Lising, M., Kapphahn, K. I., Anidi, C. M., Neuville, R., Coburn, M., Shah, N., et al. (2020) · Movement Disorders · doi:10.1002/mds.28198 · Cited by 23
Metadata
- Authors
- Ko, J.-H., Seok, H., Cho, S. Y., Ha, Y. E., Baek, J. Y., Kim, S. H., Kim, Y.-J., Park, J. K., Chung, C. R., Kang, E.-S., Cho, D., Müller, M. A., Drosten, C., Kang, C.-I., Chung, D. R., Song, J.-H., & Peck, K. R.
- Venue
- Antiviral Therapy
- Publisher
- SAGE Publications
- Published
- 2017-10-01
- Volume
- 23
- Issue
- 7
- Pages
- 617-622
- ISSN
- 1359-6535 (ISSN-L)
- 2040-2058
- OpenAlex
- W2808754971
- Cited by
- 323
- References
- 15
- FWCI
- 32.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.